Identification and susceptibility testing of oral candidiasis in advanced cancer patients

BMC Oral Health

Table 3 Susceptibility of antifungal agents on Candida isolates

Species	Number isolates N = 56	Fluconazole 0.016–256 µm/ml		Amphotericin B 0.002–32 µg/ml		Anidulafungin 0.002–32 µg/ml
		S	R	S	R	S	R
		n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
C. albicans	40	39 (98)	1 (2)	40 (100)	0	40 (100)	0
C. glabrata	5	4^a (80)	1 (20)	5 (100)	0	5 (100)	0
C. parapsilosis	3	3 (100)	0	3 (100)	0	1 (33)	2 (67)
C. tropicalis	2	2 (100)	0	1 (50)	1(50)	1 (50)	1 (50)
C. krusei	1	-	-	1 (100)	0	1 (100)	0
C. guilliermondii^b	1	IE	IE	IE	IE	IE	IE
C. dubliniensis^c	1	1 (100)	0	1 (100)	0	NR	NR
Saccharomyces cerevisiae^d	3	ND	ND	ND	ND	ND	ND

S Susceptible, R Resistant
^aNotes from EUCAST: “The entire C. glabrata is in the Intermediate category. MICs against C. glabrata should be interpreted as resistant when above 16 mg/L. Susceptible category (≤ 0.001 mg/L) is simply to avoid misclassification of "I" strains as "S" strains”
^bIE Insufficient evidence that the organism or group is a good target for therapy with the agent Fluconazole according to EUCAST
^cEUCAST: Anidulafungin not recommended for this species
^dEUCAST: Not determined

ISSN: 1472-6831